CE, MOC & Certificates

Designed for clinicians, scientists, and all other members of the cancer care and research community, this three-day meeting focuses on clinical and translational advances in immuno-oncology. At the 2018 Symposium, expert faculty will offer new insights on the application of immunotherapy in melanoma, lung cancer, genitourinary cancers, head and neck cancer, and hematologic malignancies. Faculty will also discuss considerations for clinical trial designs, the treatment of microsatellite instability high solid tumors, and emerging targets in immunotherapy. Abstract presentations will be featured in Oral Abstract Sessions and Poster Sessions.

Available Certificates

Attendees can log in to the iPlanner or CE Portal to access any of the following certificates after noting their participation:

  • Continuing Medical Education Certificate – available for physicians who would like to receive CME credits for their participation at the Symposium
  • Continuing Nursing Education Certificate – available for nurses who would like to receive CE credits for their participation at the Symposium
  • Certificate of Participation – all other attendees may request a Certificate of Participation after recording their session participation. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted.
  • Certificate of Attendance - Attendees can download a Certificate of Attendance from the Attendee Resource Center if they need a record of their attendance at the Symposium but do not require documentation for contiuing education purposes. Please note that this certificate does not award any contiuing education credits. 

For instructions on how to claim credit and access certificates, please see the 'Symposium Feedback and Credit Claim Instructions' section. Your feedback is utilized by leadership to enhance programs, develop new initiatives, gauge educational impact, and plan for future meetings. ​

Symposium Feedback and Credit Claim Instructions 

Every participant is encouraged to submit a Symposium Feedback Form, provide session ratings, and access certificates for the Symposium through the iPlanner app or CE Portal. Your feedback is utilized by leadership to enhance programs, develop new initiatives, gauge educational impact, and plan for future meetings. 

  • To provide feedback on a specific session
  1. Download the iPlanner app
  2. Select a session by searching by time or track
  3. Select "Rate This Session" to submit feedback on each session you attend 
  • To access certificates and claim credit
  1. Log in to the CE Portal using your ASCO.org username and password
  2. Select the appropriate meeting and your role
  3. Select "CME Certificate" to claim credit and download a certificate 
  • To give overall feedback on the meeting 
  1. Log in to the CE Portal using your ASCO.org username and password 
  2. Select "Provide Meeting Feedback" to submit your feedback on the symposium

To receive ABIM MOC points, participants must submit their Symposium Feedback Form and claim their CME credits in the CE Portal for the Symposium by March 1, 2018. Once both of these steps are complete, ASCO will transmit all information to ABIM on the participant’s behalf.

Accreditation and Designation Statement

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Society of Clinical Oncology designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation Statement - Nurses

The maximum number of hours awarded for this CE activity is 20.0 contact hours

AAPA/NCCPA Credit Designation Statement – PAs

PAs may claim a maximum of 20.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™from organizations accredited by ACCME or a recognized state medical society.

All non-physician attendees are welcome to submit a request for a Certificate of Participation, which may enable non-physicians to apply their meeting participation toward re-licensure. Please note, however, that all final decisions regarding certificate acceptance will be made by the licensing organization to which the certificate is submitted.

Target Audience

This Symposium is designed for physicians and researchers involved in multidisciplinary clinical cancer care including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists; nurses, pharmacists, advanced practice providers, and other health care professionals involved in clinical cancer care and cancer research in immuno-oncology.

Educational Needs Statement

The 2018 ASCO-SITC Clinical Immuno-Oncology Symposium builds on the success of its inaugural year in 2017 to provide an even greater clinical focus on the use of immunotherapy to treat patients with cancer.  Even as research efforts continue to swell in this area, there have also been a number of new immunotherapy-related approvals of both agents and diagnostics over the past year.  This has created a clear educational need for oncology professionals who are facing an increasing complexity in selecting and interpreting diagnostic tests, making treatment decisions, and managing the effects of those treatments. 

Learning Objectives

Upon participation in this activity, attendees will be able to

  • Demonstrate competence in describing immunological principles and the use of cellular therapy in treating patients with cancer;
  • Outline the effective use of genomics data when considering immunotherapy to inform both treatment selection and potential immune response;
  • Compare and contrast the use and effectiveness of immunotherapy in the treatment of patients with cancer in different disease sites, and how these experiences have informed clinical research and potentially led to drug approvals for immunotherapy that are not tissue specific;
  • Describe the unique considerations for clinical trial designs when testing immunotherapeutic agents, as well as the diagnostic tools and assays used to identify eligible participants;
  • Collaborate across different specialties and with all members of the oncology care team to provide effective and patient-centered treatment and supportive care for patients who are receiving immunotherapeutic agents;
  • Discuss emerging targets that are being explored for immunotherapy, new agents that are in development, and new biomarkers that could further improve treatment decisions and impact patient outcomes.

Disclaimer and Unlabeled Usage Statement

The information presented is that of the contributing faculty and presenters and does not necessarily represent the views of the Symposium Cosponsors and/or any named company or organization providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty or presenters. Therefore, before presenting any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.

Commercial Supporters

ASCO and Conquer Cancer gratefully awknowledge the following companies for their support of the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium:

Amgen AstraZeneca Celgene
Incyte Kite Pharmaceuticals Merck
Novartis Pfizer Oncology Prometheus